Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management von Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann

Volltext

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study von Singer, Barry A, Arnold, Douglas L, Drulovic, Jelena, Freedman, Mark S, Gold, Ralf, Gudesblatt, Mark, Jasinska, Elzbieta, LaGanke, Christopher C, Naismith, Robert T, Negroski, Donald, Oh, Jiwon, Hernandez Perez, Miguel Angel, Selmaj, Krzysztof, Then Bergh, Florian, Wundes, Annette, Ziemssen, Tjalf, Castro-Borrero, Wanda, Chen, Hailu, Levin, Seth, Scaramozza, Matthew, Shankar, Sai L, Wang, Ting, Wray, Sibyl

Volltext

Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis von Chinea, Angel, Honeycutt, William David, Miller, Tamara, Graves, Donna, Jacobs, Alan, Wu, Junlong, LaGanke, Christopher C

Volltext

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data von Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf

Volltext

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies von Dayan, Colin M., Lecumberri, Beatriz, Muller, Ilaria, Ganesananthan, Sashiananthan, Hunter, Samuel F., Selmaj, Krzysztof W., Hartung, Hans-Peter, Havrdova, Eva K., LaGanke, Christopher C., Ziemssen, Tjalf, Van Wijmeersch, Bart, Meuth, Sven G., Margolin, David H., Poole, Elizabeth M., Baker, Darren P., Senior, Peter A.

Volltext

Multifocal motor sensory demyelinating neuropathy : Inflammatory demyelinating polyradiculoneuropathy von OH, S. J, LAGANKE, C, POWERS, R, WOLFE, G. I, QUINTON, R. A, BURNS, D. K

Volltext

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings von Barclay, Krista, Carruthers, Robert, Traboulsee, Anthony, Bass, Ann D, LaGanke, Christopher, Bertolotto, Antonio, Boster, Aaron, Celius, Elisabeth G, de Seze, Jérôme, Cruz, Dionisio Dela, Habek, Mario, Lee, Jong-Mi, Limmroth, Volker, Meuth, Sven G, Oreja-Guevara, Celia, Pagnotta, Patricia, Vos, Cindy, Ziemssen, Tjalf, Baker, Darren P, Wijmeersch, Bart Van

Volltext

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial von Coles, Alasdair J, Dr, Twyman, Cary L, MD, Arnold, Douglas L, Prof, Cohen, Jeffrey A, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Miller, Tamara, MD, Fisher, Elizabeth, PhD, Sandbrink, Rupert, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Oyuela, Pedro, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial von Cohen, Jeffrey A, Prof, Coles, Alasdair J, PhD, Arnold, Douglas L, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Fisher, Elizabeth, PhD, Brinar, Vesna V, MD, Giovannoni, Gavin, Prof, Stojanovic, Miroslav, MD, Ertik, Bella I, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Cross-reactive idiotypy in cerebrospinal fluid immunoglobulins in multiple sclerosis von LaGanke, Christopher C., Freeman, Deborah W., Whitaker, John N.

Volltext

A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis von ZHOU, S.-R, MAIER, C. C, MITCHELL, G. W, LAGANKE, C. C, BLALOCK, J. E, WHITAKER, J. N

Volltext

Safety of Alemtuzumab in RRMS Patients in the Period Following Lymphocyte Repopulation: Clinical Trial and Postmarketing Experience von Jones, J, Coml, G, Fernandez, O, Kappos, L, Havrdova, EK, Laganke, C, Greja-Guevara, C, Piehl, F, Traboulsee, A, Vermersch, P, Wiendl, I, Ziemssen, T, Poole, E, Coles, AJ

Volltext

Safety of Alemtuzumab in RRMS Patients During the Peri-infusion Period: Clinical Trial and Postmarketing Experience von Vennersch, P, Bass, AD, Boster, A, Chan, A, Coles, AJ, Comic, G, Giovannoni, G, Junes, J, Kappos, L, Laganke, C, Oreja-Guevara, C, Piehl, F, Poole, E, Montalban, X

Volltext

Safety of Alemtuzumab Over 9 Years in Patients With Non-MS Autoimmunity von Coles, AJ, Bass, AD, Comi, G, Fernandez, O, Giovannoni, G, Jones, J, Kappos, L, Havrdova, EK, Laganke, C, Montalban, X, Piehl, F, Traboulsee, A, Vermersch, P, Ziemssen, T, Poole, E, Wiendl, H

Volltext

Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509) von Dayan, Colin, Lecumberri, Beatriz, Muller, Ilaria, Ganesananthan, Sashiananthan, Hunter, Samuel F., Selmaj, Krzysztof W., Hartung, Hans-Peter, Havrdova, Eva K., LaGanke, Christopher C., Ziemssen, Tjalf, Van Wijmeersch, Bart, Meuth, Sven G., Margolin, David H., Afsar, Salman, Daizadeh, Nadia, Poole, Elizabeth M., Baker, Darren P., Senior, Peter A.

Volltext

Effect of Alemtuzumab Infusions on Vital Signs von Chinea, Angel, Honeycutt, William David, Miller, Tamara, Graves, Donna, Jacobs, Alan, Wu, Junlong, LaGanke, Christopher C.

Volltext

Sensory Guillain-Barré syndrome von OH, Shin J, LAGANKE, Chris, CLAUSSEN, Gwen C

Volltext

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management von Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Janssens, Ann

Volltext

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy von Perkins, MR, Ryschkewitsch, C, Liebner, JC, Monaco, MCG, Himelfarb, D, Ireland, S, Roque, A, Edward, HL, Jensen, PN, Remington, G, Abraham, T, Abraham, J, Greenberg, B, Kaufman, C, LaGanke, C, Monson, NL, Xu, X, Frohman, E, Major, EO, Douek, DC

Volltext

Comparison of Properties of Murine Monoclonal Anti-idiotypic Antibodies Generated with Idiotype-Bearing Monoclonal Antibodies to Myelin Basic Protein Peptides or Their Complementar... von Zhou, Shan-Ren, Han, Qiao, Laganke, Christopher C., Whitaker, John N.

Volltext